(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
UN experts urge investigation into Israel’s killing of Lebanese journalists - 2Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- 3Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- 4Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- 5Are your hormones imbalanced? Doctors explain how to know if you need testing
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- 5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- How the Iran war may affect your money and bills
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- Vote in favor of the pasta that makes good dieting pleasant!
- These are the Fastest Italian Sports Cars
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- Starfront Observatories: A haven for distant stargazers
